Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Genomma Lab Internacional, S.A.B. de C.V.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • According to MSCI, the company's ESG score for its industry is good.
Highlights: Genomma Lab Internacional, S.A.B. de C.V.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Its low valuation, with P/E ratio at 6.83 and 6.54 for the ongoing fiscal year and 2027 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The stock, which is currently worth 2026 to 0.93 times its sales, is clearly overvalued in comparison with peers.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Genomma Lab Internacional, S.A.B. de C.V.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
707M
A
1,055B
A
654B -
BBB
- -
467B
AAA
-
348B
AA
275B
AAA
258B
A
224B
A
187B
AA
171B
BBB
Average 363.91B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. LAB B Stock
  4. Ratings Genomma Lab Internacional, S.A.B. de C.V.